|
GB202020002D0
|
|
Bicyclic peptide ligands specific for TNFalpha
|
|
GB202019991D0
|
|
Bicyclic pepide ligands specific for klk5
|
|
GB202019992D0
|
|
Bicyclic peptide ligands specific for KLK7
|
|
GB202019987D0
|
|
Bicyclic peptied ligans specific for chymase
|
|
GB202019994D0
|
|
Bicyclic peptide ligands specific for Cathepsin G
|
|
GB202019997D0
|
|
Bicyclic peptide ligands specific for MMP9
|
|
GB202019990D0
|
|
Bicyclic peptide ligands specific for il-6
|
|
GB202019999D0
|
|
Bicyclic peptide ligands specific for TGFbeta
|
|
GB202019985D0
|
|
Bicyclic peptide ligands specific for neutrophil elastase
|
|
GB202019988D0
|
|
Bicyclic peptide ligands specific for hsp90
|
|
GB202020005D0
|
|
Bicyclic peptide ligands specific for VEGF
|
|
GB202020003D0
|
|
Bicyclic peptide ligands specific for EphA3
|
|
GB202019993D0
|
|
Bicyclic peptide ligands specific for IL-9
|
|
WO2021074647A1
|
|
Methods for treating cancer
|
|
GB202016331D0
|
|
Bicyclic peptide ligand drug conjugates
|
|
GB202015666D0
|
|
Bicyclic peptide ligand drug conjugates
|
|
GB202015668D0
|
|
Bicyclic peptide ligands specific for cathepsin s
|
|
GB202015302D0
|
|
Ligand design
|
|
GB202015301D0
|
|
Interaction with multiple sites
|
|
US2020354456A1
|
|
Methods for treating cancer
|
